Search by Drug Name or NDC
NDC 00186-0777-08 BRILINTA 90 mg/1 Details
BRILINTA 90 mg/1
BRILINTA is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AstraZeneca Pharmaceuticals LP. The primary component is TICAGRELOR.
MedlinePlus Drug Summary
Ticagrelor is used to prevent a serious or life-threatening heart attack or stroke, or death in people who have had a heart attack or who have acute coronary syndrome (ACS; blockage of blood flow to the heart). It is also used to prevent blood clots from forming in people who have received coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow) to treat ACS. Ticagrelor is used to decrease the risk of a first-time heart attack or stroke in people at risk with coronary artery disease (CAD; reduced blood flow to the heart). It is also used to decrease the risk of another more serious stroke in people who are having a mild to moderate stroke or a transient ischemic attack (TIA; ministroke). Ticagrelor is in a class of medications called antiplatelet medications. It works by preventing platelets (a type of blood cell) from collecting and forming clots that may cause a heart attack or stroke.
Related Packages: 00186-0777-08Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ticagrelor
Product Information
| NDC | 00186-0777 |
|---|---|
| Product ID | 0186-0777_a0a0d886-ed09-4160-9bd5-f6fd51d99dd8 |
| Associated GPIs | 85158470000320 |
| GCN Sequence Number | 066950 |
| GCN Sequence Number Description | ticagrelor TABLET 90 MG ORAL |
| HIC3 | M9P |
| HIC3 Description | PLATELET AGGREGATION INHIBITORS |
| GCN | 29385 |
| HICL Sequence Number | 037328 |
| HICL Sequence Number Description | TICAGRELOR |
| Brand/Generic | Brand |
| Proprietary Name | BRILINTA |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Ticagrelor |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 90 |
| Active Ingredient Units | mg/1 |
| Substance Name | TICAGRELOR |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Pharmaceutical Class | Cytochrome P450 3A4 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P-Glycoprotein Inhibitors [MoA], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022433 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00186-0777-08 (00186077708)
| NDC Package Code | 0186-0777-08 |
|---|---|
| Billing NDC | 00186077708 |
| Package | 8 TABLET in 1 BOTTLE (0186-0777-08) |
| Marketing Start Date | 2011-08-05 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |